Avaliação das mutações em PI3K e do genótipo de HPV em pacientes com câncer cervical associados a desfechos clínicos e de sobrevida

Abstract

Objectives: To evaluate cervical cancer patients diagnosed and treated at an oncology reference institution and to analyze clinical and pathological features, survival outcomes, HPV genotype and PIK3CA mutation status; relating to HPV genotype and PIK3CA mutation status with other characteristics in this population. Methods: A retrospective observational cohort study evaluating patients treated from January 1st 2012 until December 31th 2016. Patients were identified and paraffin blocks were rescued to molecular analysis. Clinical and survival data were collected and analyzed. Results: 58 patients were included in this study. The median age was 44 years; 29.3% of the patients were smokers. The predominant histological subtype was squamous cell carcinoma (88%) and 64% of the patients were on PS1. Most patients were in advanced clinical stages, 29.3% in CS III and 48.3% in CS IV, respectively. The median follow-up was 22.8 months, 1-year and 3-year estimated progression-free survival was 66% and 44.8%, respectively. The 1-year and 3-year estimated overall survival was 79.2% and 63.4%, respectively. 40 (69%) patients showed HPV16 / HPV18 positivity and there was no statistically significant relationship between HPV status and the clinical-pathological population features and overall survival outcome, HPV 16 (p=0.550) and HPV 18 (p=0.594), respectively. Of the 58 cases analyzed, 17 (29.3%) presented PIK3CA mutation, being more frequent p.E545K (exon 9), found in 12 (20.7%) patients. There was no statistical relationship associated PIK3CA mutation with clinical-pathological characteristics and overall survival outcome (p=0.477). Conclusion: The cervical cancer patient population presented a disease profile diagnosed at more advanced stages (CS III and IVA) and aggressive clinical characteristics. PI3KCA mutations and HPV genotype 16/18 prevalence was 29.3% and 69%, respectively. No statistical significance was identified between PI3K mutations and HPV genotype 16/18 with clinical-pathological features and survival outcomes. [resumo fornecido pelo autor]